Corteva (CTVA) Investor Day 2024 summary

Strategic Vision, Growth Platforms, and Performance

• Six growth platforms—seed out-licensing, biologicals, CP new products, gene editing, biofuels, and hybrid wheat—are positioned to drive significant value, with the first three expected to add $1 billion in incremental revenue by 2027.

• Out-licensing is transitioning the company from a technology buyer to a seller, targeting net zero royalties by 2028 and net positive thereafter, with royalty neutrality now expected by 2029, a year ahead of plan.

• New CP products, including Adavelt, Reklemel, and Haviza fungicide, are expected to contribute significantly, with 150-200 new CP products planned annually through 2027 and $500M in low-margin product exits.

• Gene editing, biofuels, hybrid wheat, and biologicals are multi-billion dollar opportunities, with gene-edited corn and hybrid wheat launches targeted for 2027 and beyond.

• Partnerships with major players are expanding biofuel feedstock programs, and hybrid wheat is expected to increase yields by 10-20%, addressing global food security.

Financial Framework, Guidance, and Capital Allocation

• A new $3 billion share buyback program was announced, with $4.5 billion planned to be returned to shareholders via dividends and buybacks between 2025 and 2027.

• The 2027 financial framework targets $1 billion in incremental net revenue, $1 billion in gross productivity and cost benefits, and 100 basis points of annual EBITDA margin growth from 2025-2027.

• Operating EBITDA is projected to reach $4.4 billion by 2027, a 9% CAGR, with margins expanding nearly 400 basis points over 2024, and free cash flow expected at $2.2 billion in 2027.

• 2027 targets include net sales of $18.2–$18.8B, operating EBITDA of $4.1–$4.7B, margin expansion to 23–25%, and annual free cash flow of $1.7–$2.3B.

• Ongoing cost actions and productivity initiatives are expected to deliver ~$700M net savings over three years, with capital expenditures at 3-4% of sales.

Innovation, Technology, and Operational Excellence

• Over 2,000 new products have been launched and 7,000+ patents added since 2019, with annual operating EBITDA increased by $1.3 billion and a 10% CAGR.

• The company is leveraging AI and digital tools, including the proprietary CARL agronomy model, to accelerate R&D, product placement, and deliver tailored agronomic insights.

• Leading in gene editing with 1,400+ unique gene targets and 350+ patents, aiming to double yield improvement rates.

• The seed business has expanded margins by over 750 basis points in four years, driven by price value capture, market share gains, and royalty reductions.

• Crop protection has shifted to a differentiated, farmer-centric portfolio, with 65% of revenue from differentiated products and a biologicals business expected to double by 2030.